XBiotech to Present Positive Preliminary Survival Data on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
XBiotech to Present Positive Preliminary Survival Data on Xilonix™ at the 18th European Society of Medical Oncology’s World Congress on Gastrointestinal Cancer
  • First Time Pivotal Phase III Xilonix Data to be Unveiled at Major Scientific Congress, Including Positive Preliminary Overall Mean Survival Data for Responders
  • Developed Specifically to Treat Advanced Cancer, Xilonix is First Antibody Therapy to Neutralize Biological Activity of Interleukin-1α (IL-1a)
  • Xilonix Recently Granted Accelerated Review for Marketing Authorization by the European Medicines Agency (EMA); a decision on Xilonix approval could come as early as fourth quarter 2016

AUSTIN, Texas, May 24, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT ), developer of next generation True Human™ antibody therapies, today said its upcoming presentation of pivotal Phase III data for Xilonix™, the Company’s lead therapy developed for the treatment of advanced colorectal cancer, will include positive preliminary findings on survival. The data are being presented July 2 at the 18 th ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain.

This will be the first presentation of the Phase III data at a major scientific congress. The primary endpoint of the study was clinical response rate (CRR) after 8 weeks of therapy in patients with advanced disease and multiple symptoms known to inversely correlate with overall survival. The CRR criteria were developed in collaboration with EMA’s Scientific Advice Working Group to assess anti-tumor benefit of therapy based on control of these symptoms. Secondary endpoints evaluated paraneoplastic thrombocytosis and systemic inflammation, which also are known correlates for survival in colorectal cancer. As specified in the Phase III protocol, investigators also followed up with patients after study completion or discontinuation to assess their survival status. XBiotech will share positive preliminary results from this analysis showing a survival benefit correlating to the clinical response seen in this trial; this analysis is ongoing.

A potential breakthrough for patients with advanced colorectal cancer, Xilonix is specifically designed to target and neutralize interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis (the growth and spread of tumors), as well as mediate symptoms such as metabolic dysregulation (e.g., a cause of muscle loss and weight loss), fatigue and anxiety associated with advanced cancer.

The abstract, entitled “A Pivotal Phase III Trial of Xilonix in Advanced Colorectal Cancer,” will be presented by Dr. Tamas Hickish, Chair of the Xilonix European Phase III Study, and Consultant Medical Oncologist, Royal Bournemouth Hospital NHS Foundation Trust, UK. Colorectal cancer is the leading cause of malignancy in the industrialized world.

About True Human™ Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech’s True Human™ antibodies are 100 percent human, derived from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

The first of these therapies, Xilonix™, for advanced colorectal cancer, is in Phase III clinical trials in the United States with a Fast Track designation by the U.S. Food and Drug Administration (FDA). In Europe, Xilonix Phase III clinical trials have been completed, and the therapy is under accelerated review following the validation of its Market Authorization Application by the European Medicines Agency (EMA).

About XBiotech XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to exceed the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com .

Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contacts: XBiotech Meg Lewis mlewis@xbiotech.com +1 512.386.2983 Media liaison U.S. Mariann Caprino +1 917.242.1087 Media liaison ex-U.S. Jonathan Kearney +44 20 8618 2755; Mobile: +44 7725 925 841

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 121

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 123

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 135

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading

Top 5 Most Recently Viewed Articles

Aardvark Therapeutics Advances Obesity Treatment Research

Updated Category News Views 140

Aardvark Therapeutics Unveils New Data on Obesity Treatments Aardvark Therapeutics, Inc. (AARD) recently showcased significant insights from its metabolic obesity pipeline at the latest conference dedicated to obesity, titled ObesityWeek 2025. This presentation highlighted the promising preclinical results of their innovative drug, ARD-201, which aims to enhance glucose...

Continue Reading
ITC Holdings Corp. Welcomes Carlo Capra as New VP of Engineering

Updated Category News Views 189

ITC Holdings Corp. Names Carlo Capra as Vice President of Engineering ITC Holdings Corp. has recently announced an important leadership change with the appointment of Carlo Capra as the company's new Vice President of Engineering, effective February 26, 2026. This move follows the retirement of Joe Bennett, who has played a vital role in ITC's development during his...

Continue Reading
Safeguarding Your Rights as a WEBTOON Entertainment Shareholder

Updated Category News Views 246

Understanding Your Rights as a WEBTOON Entertainment Shareholder Shareholders are urged to take action promptly, as the time to enforce your rights may be limited. Halper Sadeh LLC, an advocacy law firm focused on shareholder rights, is exploring claims regarding potential breaches of fiduciary duties by some officers and directors of WEBTOON Entertainment Inc. (NASDAQ:...

Continue Reading
TransDigm Group Delivers Strong First Quarter Performance

Updated Category News Views 124

TransDigm Group Reports First Quarter Results for Fiscal 2025 TransDigm Group Incorporated (NYSE: TDG), recognized as a leading designer, producer, and supplier of highly engineered aircraft components, recently announced their financial outcomes for the first quarter of fiscal 2025. First Quarter Financial Highlights In this first quarter, TransDigm Group achieved...

Continue Reading
Understanding Market Movements and TEM Stock Trends

Updated Category News Views 153

Market Activity Around Tempus AI In recent trading sessions, significant bearish sentiment has emerged around Tempus AI (TEM). This shift appears to be fueled by large investors taking notable positions that raise eyebrows among retail traders seeking insights on potential market movements. The Current Trading Landscape Today, we observed unusual activity in the options...

Continue Reading